Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Submits Mozobil In U.S. And Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Stem-cell mobilizer targets a shrinking niche market, analyst tells "The Pink Sheet" DAILY.

You may also be interested in...



FDA Approves Genzyme’s Mozobil For Bone Marrow Transplant Prep

Firm gains FDA approval for Mozobil, though it likely will encounter commercialization road bumps.

FDA Approves Genzyme’s Mozobil For Bone Marrow Transplant Prep

Firm gains FDA approval for Mozobil, though it likely will encounter commercialization road bumps.

Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees

A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.

Related Content

Topics

UsernamePublicRestriction

Register

PS067926

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel